Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30471923 | 0.87 | CNR1 (0.59) | CNR1HTTL3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL24193797 | 0.87 | CNR1 (0.59) | CNR1HTTL3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL20561324 | 0.85 | CNR1 (0.64) | CNR1HTTLMNASMN1; SMN2KMT2A | |
| SCHEMBL20561326 | 0.85 | CNR1 (0.64) | CNR1HTTLMNASMN1; SMN2KMT2A | |
| SCHEMBL1676973 | 0.85 | CNR1 (0.63) | CNR1HTTL3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL23497847 | 0.84 | EPHX2 (0.66) | ALDH1A1LMNASMN1; SMN2GAAKMT2A | |
| SCHEMBL18726870 | 0.83 | ALDH1A1 (0.63) | CNR1ALDH1A1HTTL3MBTL1LMNA | |
| SCHEMBL12727839 | 0.83 | HTT (0.62) | CNR1HTTL3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL15100910 | 0.82 | LMNA (0.74) | CNR1ALDH1A1HTTL3MBTL1LMNA | |
| SCHEMBL27370216 | 0.81 | HTT (0.70) | CNR1ALDH1A1HTTL3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115003380-B | Compounds and their use for the treatment of alpha 1-antitrypsin deficiency | 森特萨制药(英国)有限公司 | 2024-04-02 | — | — | CN | claimed |
| EP-4072671-A1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF a1-ANTITRYPSIN DEFICIENCY | Z Factor Limited (GB) | 2022-10-19 | — | — | EP | claimed |
| CN-115003380-A | Compounds and their use for the treatment of alpha 1-antitrypsin deficiency | Z因子有限公司 | 2022-09-02 | — | — | CN | claimed |
| WO-2021116703-A1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY | Z Factor Limited (GB) | 2021-06-17 | — | — | WO | claimed |
| US-7407977-B2 | Substituted N-acyl-2-aminothiazoles | HOFFMAN-LA ROCHE INC. (US) | 2008-08-05 | — | — | US | claimed |
| US-20060030589-A1 | Substituted N-acyl-2-aminothiazoles | HOFFMANN-LA ROCHE INC. | 2006-02-09 | — | — | US | claimed |
| EP-4072671-B1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY | CENTESSA PHARMACEUTICALS UK LTD (GB) | 2025-09-17 | — | — | EP | disclosed |
| CN-115003380-B | Compounds and their use for the treatment of alpha 1-antitrypsin deficiency | 森特萨制药(英国)有限公司 | 2024-04-02 | — | — | CN | disclosed |
| WO-2022263829-A1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY | Z Factor Limited (GB) | 2022-12-22 | — | — | WO | disclosed |
| EP-4072671-A1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF a1-ANTITRYPSIN DEFICIENCY | Z Factor Limited (GB) | 2022-10-19 | — | — | EP | disclosed |
| CN-115003380-A | Compounds and their use for the treatment of alpha 1-antitrypsin deficiency | Z因子有限公司 | 2022-09-02 | — | — | CN | disclosed |
| WO-2021116703-A1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY | Z Factor Limited (GB) | 2021-06-17 | — | — | WO | disclosed |
| US-7407977-B2 | Substituted N-acyl-2-aminothiazoles | HOFFMAN-LA ROCHE INC. (US) | 2008-08-05 | — | — | US | disclosed |
| CN-1993336-A | Substituted n-acyl-2-aminothiazoles | HOFFMANN LA ROCHE (CH) | 2007-07-04 | — | — | CN | disclosed |
| US-20060030589-A1 | Substituted N-acyl-2-aminothiazoles | HOFFMANN-LA ROCHE INC. | 2006-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030589-A1 | Substituted N-acyl-2-aminothiazoles | SLC5A2, ABAT, AGTR2 | CNR1 1730/4885ALDH1A1 491/4885HTT 2587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.